SCHEMBL479199

SCHEMBL479199

CCCCCCCCCCCCCCCCCC(=O)O[C@@H](CO)C(OP(=O)([O-])OCC[N+](C)(C)C)C(=O)CCCCCCCCCCCCC

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.59
NR5A2 O00482 1/20 0.59
NR5A1 Q13285 1/20 0.59
RECQL P46063 1/20 0.57
MAPT P10636 1/20 0.54
LMNA P02545 1/20 0.53
ESR1 P03372 1/20 0.53
ADORA3 P0DMS8 1/20 0.53
CDC25A P30304 1/20 0.53
AGTR1 P30556 1/20 0.53
AKT1 P31749 1/20 0.53
ADRA1A P35348 1/20 0.53
KCNH2 Q12809 1/20 0.53
ALDH1A1 P00352 1/20 0.51
ADRA1D P25100 1/20 0.50
PTAFR P25105 1/20 0.50
HTR1D P28221 1/20 0.50
HTR2C P28335 1/20 0.50
ADRA1B P35368 1/20 0.50
DRD3 P35462 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7753858 1.00 SMN1; SMN2 (0.59) SMN1; SMN2NR5A2NR5A1RECQLMAPT
SCHEMBL479274 1.00 SMN1; SMN2 (0.59) SMN1; SMN2NR5A2NR5A1RECQLMAPT
SCHEMBL672865 1.00 SMN1; SMN2 (0.59) SMN1; SMN2NR5A2NR5A1RECQLMAPT
SCHEMBL671970 1.00 SMN1; SMN2 (0.59) SMN1; SMN2NR5A2NR5A1RECQLMAPT
SCHEMBL479150 1.00 SMN1; SMN2 (0.59) SMN1; SMN2NR5A2NR5A1RECQLMAPT
SCHEMBL14967280 1.00 SMN1; SMN2 (0.59) SMN1; SMN2NR5A2NR5A1RECQLMAPT
SCHEMBL673766 1.00 SMN1; SMN2 (0.59) SMN1; SMN2NR5A2NR5A1RECQLMAPT
SCHEMBL2930405 0.96 SMN1; SMN2 (0.55) SMN1; SMN2NR5A2NR5A1RECQLMAPT
SCHEMBL37559 0.94 ALDH1A1 (0.60) SMN1; SMN2NR5A2NR5A1RECQLMAPT
SCHEMBL672371 0.94 ALDH1A1 (0.60) SMN1; SMN2NR5A2NR5A1RECQLMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4577196-A1 LIPID NANOPARTICLE (LNP) COMPOSITION OR FORMULATION FOR NUCLEIC ACID THERAPEUTICS Popvax Private Limited (IN) 2025-07-02 EP claimed
WO-2024044178-A1 LIPID NANOPARTICLE (LNP) COMPOSITION OR FORMULATION FOR NUCLEIC ACID THERAPEUTICS POPVAX PRIVATE LIMITED (IN) 2024-02-29 WO claimed
EP-4017537-A1 SILK PERSONAL CARE COMPOSITIONS Evolved by Nature, Inc. (US) 2022-06-29 EP claimed
WO-2021216572-A1 LIPID COMPOSITIONS FOR DELIVERY OF STING AGONIST COMPOUNDS AND USES THEREOF MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2021-10-28 WO claimed
WO-2021035087-A1 SILK PERSONAL CARE COMPOSITIONS EVOLVED BY NATURE, INC. (US) 2021-02-25 WO claimed
WO-2020243047-A1 CONTROLLED HEAT DELIVERY COMPOSITIONS BAMBU VAULT LLC (US) 2020-12-03 WO claimed
EP-3458083-A1 POLYNUCLEOTIDES ENCODING INTERLEUKIN-12 (IL12) AND USES THEREOF Modernatx, Inc. (US) 2019-03-27 EP claimed
EP-3458092-A1 MRNA COMBINATION THERAPY FOR THE TREATMENT OF CANCER Modernatx, Inc. (US) 2019-03-27 EP claimed
WO-2017201352-A1 MRNA COMBINATION THERAPY FOR THE TREATMENT OF CANCER MODERNATX, INC. (US) 2017-11-23 WO claimed
WO-2017201350-A1 POLYNUCLEOTIDES ENCODING INTERLEUKIN-12 (IL12) AND USES THEREOF MODERNATX, INC. (US) 2017-11-23 WO claimed
WO-2017004518-A1 SITE-TARGETED NANO-LIPOSOMAL NITROGLYCERIN THERAPEUTICS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-01-05 WO claimed
WO-2010030739-A1 POLYETHYLENE GLYCOL LIPID CONJUGATES AND USES THEREOF ABBOTT LABORATORIES (US) 2010-03-18 WO claimed
WO-2009129395-A1 CATIONIC LIPIDS AND USES THEREOF ABBOTT LABORATORIES (US) 2009-10-22 WO claimed
EP-1536831-A2 PHARMACEUTICAL LIPOSOMAL COMPOSITIONS CONTAINING N. MENINGITIDIS DERIVED POLYPEPTIDES OR POLYNUCLEOTIDES ID Biomedical Corporation (CA) 2005-06-08 EP claimed
WO-2004019976-A2 PHARMACEUTICAL LIPOSOMAL COMPOSITIONS CONTAINING N. MENINGITIDIS DERIVED POLYPEPTIDES OR POLYNUCLEOTIDES ID BIOMEDICAL CORPORATION (CA) 2004-03-11 WO claimed
EP-4743090-A1 LIPOSOME ENCAPSULATED APOMORPHINE Liposome Holdings Limited (NZ) 2026-05-20 EP disclosed
WO-2026090590-A1 NANOPARTICLE FORMULATIONS FOR THE DELIVERY OF DNA TO ADIPOSE TISSUE Remedium Bio, Inc. (US) 2026-04-30 WO disclosed
WO-2005107820-A1 COMPOSITIONS AND METHODS FOR ENHANCING CONTRAST IN IMAGING MARVEL THERAPEUTICS (US) 2005-11-17 WO disclosed
EP-1487411-A2 INHALABLE SUSTAINED THERAPEUTIC FORMULATIONS Advanced Inhalation Research, Inc. (US) 2004-12-22 EP disclosed
WO-2003079885-A2 INHALABLE SUSTAINED THERAPEUTIC FORMULATIONS ADVANCED INHALATION RESEARCH, INC. (US) 2003-10-02 WO disclosed